Pharming Group ( (PHAR) ) has issued an announcement.
On February 20, 2025, Pharming Technologies B.V., a subsidiary of Pharming Group N.V., announced an increase in its ownership of Abliva AB to 92.70% following a cash offer to Abliva shareholders made in December 2024. The offer was initially accepted by 87.71% of shareholders by February 7, 2025, and the ownership stake was further increased through additional share acquisitions. Pharming plans to initiate a compulsory acquisition for the remaining shares and aims to delist Abliva from Nasdaq Stockholm, indicating a strategic move to consolidate its holdings and strengthen its market position in the biopharmaceutical sector.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on improving the lives of patients with rare, debilitating, and life-threatening diseases. The company specializes in commercializing and developing a portfolio of innovative protein replacement therapies and precision medicines, including small molecules and biologics. Headquartered in Leiden, the Netherlands, Pharming operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific.
YTD Price Performance: -18.55%
Average Trading Volume: 6,808
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $629.6M
Find detailed analytics on PHAR stock on TipRanks’ Stock Analysis page.